Chemistry:MMDA-2

From HandWiki
Short description: Psychedelic drug
MMDA-2
MMDA-2-structure.png
Clinical data
Routes of
administration
Oral, Insufflated, Rectal
ATC code
  • none
Legal status
Legal status
  • CA: Schedule I
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC11H15NO3
Molar mass209.245 g·mol−1
3D model (JSmol)

MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class.[1] It is closely related to MMDA and MDA.[1]

Alexander Shulgin was likely the first to synthesize MMDA-2.[1] In his book PiHKAL, the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours.[1] Shulgin reports that MMDA-2 produces effects such as enhanced awareness, empathy, and visual facilitation and distortion, as well as some side effects like gastrointestinal upset and appetite loss.[1] He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose.[1]

Scientific research has shown that MMDA-2, unlike MMDA, but similarly to 6-methyl-MDA, is only very weak at inducing the release of serotonin or dopamine,[2] and accordingly, does not produce amphetamine-like responses in animals in drug discrimination studies.[3] Instead, MMDA-2 is likely to act as a pure 5-HT2 receptor agonist similarly to the DOx series of compounds, with activation of the 5-HT2A receptor conferring its psychedelic effects.[4]

MMDA-2 has been sold as a designer drug in Japan .[5]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 "MMDA-2 (2-Methoxy-4,5-methylenedioxyamphetamine)". Pihkal: A Chemical Love Story. Transform Press. 13 May 2016. ISBN 978-0-9630096-0-9. http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=133. 
  2. "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacology, Biochemistry, and Behavior 38 (3): 505–512. March 1991. doi:10.1016/0091-3057(91)90005-M. PMID 1829838. 
  3. "Methcathinone: a new and potent amphetamine-like agent". Pharmacology, Biochemistry, and Behavior 26 (3): 547–551. March 1987. doi:10.1016/0091-3057(87)90164-X. PMID 3575369. 
  4. "QSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens". Journal of Computer-Aided Molecular Design 16 (8–9): 611–633. 2002. doi:10.1023/A:1021966231380. PMID 12602954. Bibcode2002JCAMD..16..611C. 
  5. "Simultaneous determination of 11 designated hallucinogenic phenethylamines by ultra-fast liquid chromatography with fluorescence detection". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 873 (2): 187–194. October 2008. doi:10.1016/j.jchromb.2008.08.020. PMID 18789774. 

External links